Small molecule · developed by BioMarin Pharmaceutical
Tetrahydrobiopterin is a cofactor essential for the activity of aromatic amino acid hydroxylases. It supports phenylalanine degradation, neurotransmitter biosynthesis and nitric oxide production, and is studied in intermittent claudication and peripheral artery disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04800692 | Phase 1 | Claudication, Intermittent | Active not recruiting | BMRN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Claudication, IntermittentPeripheral Artery DiseasePeripheral Vascular Diseases
Updated Nov 8, 2026. Something wrong or missing? Report it on the BMRN page.
See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BMRN catalysts and pipeline →